Menarini launches PRIME MDx platform

  1. Menarini Diagnostics has launched its new PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.

The COVID-19 pandemic has significantly reshaped the molecular diagnostics market, pushing it in the direction of seamless automation, ease-of-use, fast turnaround times and test reliability. In spite of the significant advances in the domain, several testing applications still rely on laboratory-developed tests and labour-intensive techniques which make the implementation of large-scale automated diagnostics solutions inconvenient.

In response to these needs and market dynamics, A.Menarini Diagnostics rose to the challenge and coordinated the development of a brand new solution, relying on the skills of its R&D department with Italian and international partners.

PRIME MDx allows users to process a range of sample types thanks to the clever adoption of pre-filled plates together with universal extraction solution, running up to five different assays per sample for a maximum capacity of 240 samples per day.

The AI-driven software ensures a flawless customer experience, from continuous sample loading to result interpretation.

The system will be launched on the market with two panels of tests, one for viral upper respiratory-tract infections and one for viral transplant infections on a broad spectrum of sample matrices. Other testing panels are currently in development to complete the offer.

"We are proud to bring this innovative, all-in-one, molecular diagnostics solution to the market, which will allow us to address the needs of medium- to high-throughput laboratories internationally and strengthen the position of A. Menarini Diagnostics in the molecular space," commented Fabio Piazzalunga, General Manager and Global Head of Diagnostics Division in Menarini Group.


Latest Issues